An update on the pharmacological treatment of obsessive-compulsive disorder
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The purpose of this article is to introduce the reader to an updated evidence-based drug treatment algorithm to be employed in patients with obsessive-compulsive disorder (OCD). Relevant studies were identified through a comprehensive review and classified according to the type of patients enrolled, the quality of the study design and the invasiveness, availability and complexity of the therapeutic approach. When ineffective, therapeutic trials with first-line strategies (such as the selective serotonin re-uptake inhibitors [SSRIs] and venlafaxine) should be followed by treatment approaches such as clomipramine, augmentation with antipsychotics or pindolol, SSRI megadoses or cognitive behavioral therapy. These therapeutic strategies are expected to help most patients with OCD. Additional approaches include intravenous clomipramine, oral morphine, 'heroic drug strategies', deep brain stimulation and functional neurosurgery. Independent studies are urgently needed to help identify the most promising drug treatment sequences for OCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Existence of Publication Bias and Risk Factors for Its Occurrence
Dickersin, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100097014 · Cited by 1,417 · cited 1×
“Publication bias is the tendency on the parts of investigators, reviewers and editors to submit or accept manuscripts for publication based on the direction or strength of the study findings [210].”
BackgroundBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 2×
“Selected articles included not only treatment trials, but also key meta-analytical [12-20], systematic [5,6,21] and narrative reviews [22-24], as well as treatment guidelines and recommendations from several different professional societies, including the Canadian Psychiatric Association [25], the British Association…”
BackgroundMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
Clomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497
Abramowitz, J. S. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.65.1.44 · Cited by 490
Eddy, K. T., Dutra, L., Bradley, R., & Westen, D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.08.004 · Cited by 475 · cited 1×
“Selected articles included not only treatment trials, but also key meta-analytical [12-20], systematic [5,6,21] and narrative reviews [22-24], as well as treatment guidelines and recommendations from several different professional societies, including the Canadian Psychiatric Association [25], the British Association…”
BackgroundPallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408 · cited 24×
“(2007) 8(5) 565 'Heroic drug strategies': non-tested 'off-label' drug combinations including SSRI, clomipramine or venlafaxine plus drugs targeted to dopaminergic (e.g., amilsulpiride), serotonergic (e.g., clomipramine, triptophan, triptans, fenfluramine and perospirone), noradrenergic (e.g., reboxetine), glutamatergi…”
BackgroundMethodInfluentialEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Deep Brain Stimulation for Neurologic and Neuropsychiatric Disorders
Wichmann, T., & DeLong, M. R. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.022 · Cited by 331 · cited 3×
“Although this technique has been more frequently used by neurologists and neurosurgeons in the management of Parkinson’s disease, dystonia, tremor and epilepsy [94-96], a handful of studies have suggested that it may also help patients with treatment-resistant psychiatric disorders, including OCD [97-103].”
BackgroundMethodRiluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 2×
“These drug combinations generally consisted of an SSRI, clomipramine or venlafaxine plus a drug with an action on another neurotransmitter system, including different dopaminergic (amilsulpiride [57]), serotonergic (clomipramine [58], triptophan [59], triptans [60], fenfluramine [61], and perospirone [62]), noradrener…”
Background
Cited by
Nutritional therapies for mental disorders
Lakhan, S. E., & Vieira, K. F. (2008) · Nutrition Journal · doi:10.1186/1475-2891-7-2 · Cited by 272
Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
Self-citationSayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105
Schaffer, D. R., Okhravi, H. R., & Neumann, S. A. (2021) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acaa095 · Cited by 16
Metadata
- Authors
- Fontenelle, L. F., Nascimento, A. L., Mendlowicz, M. V., Shavitt, R. G., & Versiani, M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2007-03-22
- Volume
- 8
- Issue
- 5
- Pages
- 563-583
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2042922841
- Cited by
- 42
- References
- 27
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update on the pharmacological treatment of obsessive-compulsive disorder. https://app.cochat.ai/papers/10.1517/14656566.8.5.563
- The paper
- Fontenelle, L. F., Nascimento, A. L., Mendlowicz, M. V., Shavitt, R. G., & Versiani, M. (2007). An update on the pharmacological treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.8.5.563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.